Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements for Sir Andrew Witty and his connected persons on March 28, 2013:
- Transfer of 505 Ordinary Shares from Sir Andrew's holding and repurchase of 500 shares into an ISA at prices of 1538.582p and 1538.32p respectively.
- Transfer of 170 Ordinary Shares from a bare trust and repurchase of 165 shares into an ISA at prices of 1527.50p and 1546.17p respectively.
- Transfer of 734 Ordinary Shares from a bare trust and repurchase of 728 shares into an ISA at prices of 1539.082p and 1539.14p respectively.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rule 3.1.4R(1)(a) and (c) regarding director transactions.
Investor Verification Points
- Verify the total number of shares transferred and repurchased by Sir Andrew Witty and connected persons on March 28, 2013.
- Confirm the transaction prices per share, which ranged between approximately 1527p and 1546p.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for financial metrics.